Bausch Health Companies Inc [BHC] stock is trading at $9.86, up 4.01%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BHC shares have gain 3.35% over the last week, with a monthly amount glided 9.68%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma. In a post published today on Yahoo Finance, Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced that it is supporting a Phase 2 investigator-initiated study (IIS) of RELISTOR® (methylnaltrexone bromide: MNTX) in patients with resectable head and neck squamous cell carcinoma. An IIS is a study that is proposed, developed, and conducted by a qualified sponsor external to Bausch Health
From an analyst’s perspective:
Bausch Health Companies Inc [NYSE: BHC] stock has seen the most recent analyst activity on September 20, 2023, when Jefferies upgraded its rating to a Buy and also boosted its price target to $16 from $9. Previously, TD Cowen downgraded its rating to Market Perform on June 16, 2023. On July 29, 2022, downgrade downgraded it’s rating to Hold. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $5 on July 29, 2022. JP Morgan downgraded its rating to a Neutral. In a note dated March 24, 2021, BofA Securities downgraded an Underperform rating on this stock but restated the target price of $27.
Bausch Health Companies Inc [BHC] stock has fluctuated between $5.57 and $10.15 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Bausch Health Companies Inc [NYSE: BHC] shares were valued at $9.86 at the most recent close of the market. An investor can expect a potential drop of -8.72% based on the average BHC price forecast.
Analyzing the BHC fundamentals
Bausch Health Companies Inc [NYSE:BHC] reported sales of 8.76B for the trailing twelve months, which represents a growth of 9.80%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at -0.04%, and Net Profit Margin reading is -0.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.01, Equity is 0.17 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-21.91.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.58 points at the first support level, and at 9.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.04, and for the 2nd resistance point, it is at 10.21.
Bausch Health Companies Inc [BHC] reported earnings per share of $1.15 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.02/share, meaning a difference of $0.13 and a surprise factor of 12.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $1.02 per share as compared to estimates of $0.92 per share, a difference of $0.1 representing a surprise of 10.90%.
Ratios To Look Out For
For context, Bausch Health Companies Inc’s Current Ratio is 1.30. Also, the Quick Ratio is 0.94, while the Cash Ratio stands at 0.22. Considering the valuation of this stock, the price to sales ratio is 0.41.
Transactions by insiders
Recent insider trading involved Carson Seana, EVP, General Counsel, that happened on Mar 04 ’24 when 6313.0 shares were sold. EVP, General Counsel, Carson Seana completed a deal on Dec 05 ’23 to sell 220.0 shares. Meanwhile, EVP, General Counsel Carson Seana sold 43.0 shares on Nov 06 ’23.
